Opinion|Videos|February 16, 2026
Best Practices for APP Collaboration in Alzheimer Disease Care
Author(s)Ken Cohen, MD, FACP
Panelists discuss how multidisciplinary collaboration optimizes Alzheimer care coordination.
Advertisement
Episodes in this series
Panelists discuss how effective teamwork among advanced practice providers (APPs), neurologists, and primary care providers leads to better outcomes. They stress role clarity, mutual respect, and open communication as essential to coordinated care.
Panelists discuss how shared documentation systems and interdisciplinary meetings foster consistency and prevent duplication of effort. APPs often serve as communication hubs, ensuring continuity between visits.
Panelists discuss how this collaborative framework allows for more comprehensive management of complex Alzheimer cases, improving both efficiency and patient satisfaction.
Advertisement
Related to this article
Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.
Bispecific programs differ by practice size, but shared core components can guide adaptation, experts said at a webinar for the Bispecifics Network.
Bipolar disorder often goes undiagnosed for years, and clinicians need to separate mood episodes from normal emotions and keep patients on treatment.
A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.
Two machine learning models identifies MASLD in lean adults using 8 routine clinical measurements.
Pharmacists are moving beyond order verification into patient education, adverse effect mitigation, and parts of toxicity triage in bispecific care.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
HHS Draft Policy Eases Enforcement on 6 Compounded Peptides
3
5 Things to Know About HHS's Interim Peptide Compounding Policy
4
Elagolix Noninferior to Dienogest for Endometriosis Pain in Phase 3 Trial
5